Bijan Almassian
Amministratore Delegato presso CaroGen Corp.
Profilo
Bijan Almassian founded CaroGen Corp.
in 2012, where he is working as Chairman & Chief Executive Officer from 2012.
Dr. Almassian also formerly worked at ExSAR Corp., as President & Chief Executive Officer, Genelabs Technologies, Inc., as Director-Pharmaceutical Development, Vion Pharmaceuticals, Inc., as Vice President-Drug & Corporate Development, and Panacea Pharmaceuticals, Inc., as Chief Operating Officer.
Dr. Almassian received his doctorate degree from Massachusetts College of Pharmacy & Health Science and graduate degree from Northeastern University.
Posizioni attive di Bijan Almassian
Società | Posizione | Inizio |
---|---|---|
CaroGen Corp.
CaroGen Corp. BiotechnologyHealth Technology CaroGen Corp. operates as a vaccine company. It creates and develops virus-like-vesicle based nanoparticle vaccines to address a broad range of infectious and chronic diseases. The company was founded by Bijan Almassian, John Rose, Michael Robek and Valerian Nakaar on November 16, 2012 and is headquartered in Hamden, CT. | Amministratore Delegato | 16/11/2012 |
Precedenti posizioni note di Bijan Almassian
Società | Posizione | Fine |
---|---|---|
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Corporate Officer/Principal | - |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | Direttore operativo | - |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Corporate Officer/Principal | - |
ExSAR Corp.
ExSAR Corp. Pharmaceuticals: MajorHealth Technology ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases. | Amministratore Delegato | - |
Formazione di Bijan Almassian
Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
Northeastern University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 5 |
---|---|
ExSAR Corp.
ExSAR Corp. Pharmaceuticals: MajorHealth Technology ExSAR has offered drug discovery services to pharmaceutical, biotechnology and academic laboratories since its founding in 1997. In 2005, ExSAR initiated a program of collaborative research relationships to discover new therapeutics for the treatment of protein misfolding disorders. The aim is to become the leading drug developer in a rapidly growing $10+ billion market in metabolic and neurodegenerative disorders. Many of these disorders are characterized by mutations which lead to protein misfolding and instability followed subsequently by protein degradation. Many of these diseases currently lack any effective treatment. ExSAR is now a clinical developmental stage company dedicated to identifying, developing and commercializing small-molecule therapeutics for diseases of protein conformation. ExSAR expects to initiate clinical studies for the treatment of Tay Sachs, Sandhoff and Gaucher Diseases. | Health Technology |
Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Panacea Pharmaceuticals, Inc. develops precision cancer therapeutic products. The company was founded by Hossein A. Ghanbari and Kasra Ghanbari in 1999 and is headquartered in Gaithersburg, MD. | Health Technology |
Vion Pharmaceuticals, Inc.
Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Vion Pharmaceuticals, Inc. develops therapeutics for the treatment of cancer. The company was founded in March 1992 and is headquartered in New Haven, CT. | Health Technology |
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Health Technology |
CaroGen Corp.
CaroGen Corp. BiotechnologyHealth Technology CaroGen Corp. operates as a vaccine company. It creates and develops virus-like-vesicle based nanoparticle vaccines to address a broad range of infectious and chronic diseases. The company was founded by Bijan Almassian, John Rose, Michael Robek and Valerian Nakaar on November 16, 2012 and is headquartered in Hamden, CT. | Health Technology |
- Borsa valori
- Insiders
- Bijan Almassian